HIV Vaccine Ineffective, Study Concludes
American Forces Press Service
WASHINGTON, Apr. 25, 1996 A five-year trial of a candidate vaccine for HIV treatment ended in failure, U.S. Army Medical Research and Materiel Command officials announced April 17.
Investigators hoped the vaccine, gp160, would slow the virus' progression to AIDS, but study results show no clinical improvement attributable to the vaccine.
Although the vaccine did not slow the disease, investigators said, it did generate an elevated immune response in vaccinated subjects, and it had no adverse effects.
Enrollment of volunteers for the study began in November 1990. When follow-up with volunteers ended in December, 608 study subjects had been given regular injections of either the vaccine or a placebo every two months. Of those enrolled, 483 completed the study, 104 dropped out and 21 died before the study was completed. Compliance and follow-up with the study was 83 percent.
Medical researchers at the Walter Reed Army Institute of Research conducted the study in collaboration with Army, Navy and Air Force physicians, the National Institute of Allergy and Infectious Diseases and civilian medical centers in the United States. Microgenesys Inc. of Meriden, Conn., provided the vaccine.